Marielle B.
- Country
- Belgium
- Department
- Hematology
Research Overview
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
- Safety and Tolerability of REGN17235 in Adults with Clonal Cytopenia of Undetermined Significance or Low‑Risk SF3B1‑Mutated Myelodysplastic Syndrome
- Phase 1 Study of JNJ-95804306 in Relapsed or Refractory AML, CLL, Higher‑Risk MDS, and SLL
Data & Insights
Has run more than one trial at 58 of 147 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating myelodysplastic syndrome (MDS), with particular expertise across different risk categories of the condition. Their research encompasses both lower-risk and higher-risk MDS patient populations.
- Lower-risk MDS management
- Higher-risk MDS treatment approaches
- Novel therapeutic combinations
A key focus is on developing treatments for anemia associated with MDS.
Treatment Innovation
The investigator studies innovative therapeutic approaches for hematologic malignancies, with emphasis on combination treatments and novel agents. Their work includes evaluation of targeted therapies and standard-of-care combinations.
- Targeted therapeutic agents
- Combination therapy approaches
- Treatment-naïve patient populations
Research focuses on improving survival outcomes in newly diagnosed patients.
Clinical Outcomes
The investigator evaluates critical clinical endpoints in hematologic disorders, including transfusion independence and hemoglobin response in MDS patients. Their research addresses both quality of life and survival measures.
- Blood transfusion independence
- Overall survival assessment
- Hemoglobin response evaluation
Emphasis is placed on measuring therapeutic efficacy through objective clinical parameters.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.